Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046696 · ClinicalTrials.gov registry record · Phase 1
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00046696 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 32 participants.
The verdict
NCT00046696, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
Interventions
- DRUG NM-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2001-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046696
The ClinicalTrials.gov registry entry for NCT00046696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NM-3 is the first listed.
NCT00046696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046696 about?
NCT00046696 is a clinical study titled "A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.". A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
What is the current status of trial NCT00046696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2001-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00046696?
The interventions under investigation include: NM-3 (DRUG).
Who is sponsoring clinical trial NCT00046696?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.